Combined Liver Surgery and RFA for Patients With Gastroenteropancreatic Endocrine Tumors Presenting With More Than 15 Metastases to the Liver

Eur J Surg Oncol. 2009 Oct 1;35(10):1092-1097, D Elias, D Goéré, G Leroux, C Dromain, S Leboulleux, Th de Baere, M Ducreux, E Baudin

ABSTRACT

Aim: The aim of this study was to report the feasibility and early survival results of liver metastases (LM) resection combining cytoreductive surgery and radiofrequency ablation (RFA) during a one-step procedure, in patients presenting more than 15 bilateral LM from well-differentiated endocrine carcinoma. It is an extensive application of the current guidelines.

Methods: In this retrospective review of a prospectively collected database, we used a combination of hepatectomy to treat large or contiguous LM, and extensively used multiple RFA to treat the remaining LM which were smaller than 2.5 cm. Patients were selected based on a low natural tumor burden slope, and the technical feasibility of treating all the detectable LM.

Results: From January 2002 to May 2007, 16 patients with a median of 23 LM per patient (mean number: 25.7 + 12; range16-89) underwent this procedure. A mean of 15 + 9 LM per patient were surgically removed and a mean of 12 + 8 (median of 10) LM per patient were RF ablated. No mortality occurred. Morbidity was observed in 11 patients (69%). The 3-year overall survival and disease-free survival rates were similar to those observed in our preliminary series of 47 hepatectomized patients with a median of 7 LM per patient.

Conclusion: This new one-step combined technique allowed us to apply an ‘‘upgraded’’ therapeutic approach to a selection of patients presenting a median of 23 LM per patient and to improve their prognosis, putting it on par with that obtained by conventional hepatectomy. 

NOT A MEMBER?

OncologySTAT registration is FREE and takes less than a minute to complete. Registration provides instant access to 100+ Elsevier cancer-related journals, journal scans, daily medical and regulatory news, professional drug and interactions databases, chemotherapy regimens, and InfoBLAST - OncologySTAT's weekly e-newsletter.

 

Editors' Choice

FDG-PET Identifies Refractory HL Patients Suitable for Auto-SCT

Sign up for our newsletters

Too busy to follow cancer's top stories? Sign-up for 1 or more of our free newsletters -- delivered weekly to your inbox.

Cancer Type

  • Bladder
  • Bone
  • Breast
  • Breast (ER-Positive)
  • CNS/Brain
  • Colon and Rectum
  • Endocrine System
  • Esophagus
  • GYN (Non-Ovary)
  • GYN (Ovary)
  • Head and Neck
  • Hodgkin's Lymphoma
  • Kidney (Renal Cell)
  • Leukemia
  • Liver and Bile Duct
  • Lung
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myeloproliferative Diseases
  • Non-Hodgkin's Lymphoma
  • Pancreas
  • Pediatric Cancers
  • Prostate
  • Rare Cancers
  • Skin
  • Soft-Tissue Sarcoma
  • Stomach
  • Testicle
  • Forgot your password?
    Not a member? Free registration